Developing imaging strategies for castration resistant prostate cancer

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST

(2012) Colleen M. Costelloe et al.   Journal of Cancer

Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

(2010) G. S. P. Meirelles et al.   CLINICAL CANCER RESEARCH

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

(2010) S. N. Khleif et al.   CLINICAL CANCER RESEARCH

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

(2010) J. P. Holland et al.   JOURNAL OF NUCLEAR MEDICINE

Pharmacokinetic Assessment of the Uptake of 16 -18F-Fluoro-5 -Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET

(2010) B. J. Beattie et al.   JOURNAL OF NUCLEAR MEDICINE

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research

(2009) Michael J. Morris et al.   Clinical Genitourinary Cancer

Improved Classifications of Planar Whole-Body Bone Scans Using a Computer-Assisted Diagnosis System: A Multicenter, Multiple-Reader, Multiple-Case Study

(2009) M. Sadik et al.   JOURNAL OF NUCLEAR MEDICINE

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Surrogate and Mediating Endpoints: Current Status and Future Directions

(2009) Ross L. Prentice   JNCI-Journal of the National Cancer Institute

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy

(2009) Kenji Kuroda et al.   PROSTATE

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

(2009) P F Mulders et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Targeting the androgen receptor pathway in prostate cancer

(2008) Yu Chen et al.   CURRENT OPINION IN PHARMACOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy

(2008) N. Pandit-Taskar et al.   JOURNAL OF NUCLEAR MEDICINE

Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer

(2008) A. B. Apolo et al.   JOURNAL OF NUCLEAR MEDICINE

Computer-Assisted Interpretation of Planar Whole-Body Bone Scans

(2008) M. Sadik et al.   JOURNAL OF NUCLEAR MEDICINE

Strategic paths for biomarker qualification

(2008) Federico M. Goodsaid et al.   TOXICOLOGY